Colombian consensus for the management of patients with hypophosphatasia

Main Article Content

Juan Carlos Prieto Rivera
Adriana de la Torre
Miguel Galbán
Juan Pablo Llano
Natalia Mejía
Ana María Zarante
Johana Acosta
Manuel Alfaro
Pilar Amado
Diana Carolina Bello-Márquez
Mariangel Castillo
Johana Correa
Asid Rodríguez
Clara Corredor
Gilberto Herrera
Oswaldo Lazala
Juan Javier López-Rivera
Liliana Mejía
Jorge Luis Ordoñez
Harry Pachajoa
Tatiana Pineda
Mayerly Prada
Carolina Rivera
Jorge Rojas
Carlos Silvera

Abstract

Hypophosphatasia (HPP) is a hereditary metabolic disease caused by mutations in the ALPL gene. Taking into account the challenges found in the adequate management of patients with HPP, an interdisciplinary consensus of experts (pediatric endocrinologists, pediatric nephrologists, pediatric orthopedists and clinical geneticists) was carried out, in order to propose recommendations of clinical utility for the diagnosis, treatment and follow up of Colombian patients with HPP. These suggestions are made in the context of the different types of presentations and the ages of the patients.

Downloads

Download data is not yet available.

Article Details

How to Cite
Prieto Rivera, J. C., de la Torre, A., Galbán, M., Llano, J. P., Mejía, N., Zarante, A. M., … Silvera, C. (2019). Colombian consensus for the management of patients with hypophosphatasia. Pediatría, 52(1), 1–7. https://doi.org/10.14295/p.v52i1.103
Section
Review topics
Author Biography

Juan Carlos Prieto Rivera, Instituto de Genetica Humana, Universidad Javeriana

ext. 2792

References

1. Rathbun J. Hypophosphatasia; a new developmental anomaly. Am J Dis Child. 1948;75(6):822-31.

2. Bianchi ML. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int. 2015;26(12):2743-57. doi: 10.1007/s00198-015-3272-1.

3. Millán JL, Plotkin H. Hypophosphatasia - pathophysiology and treatment. Actual Osteol. 2012;8(3):164-82.

4. Fraser D. Hypophosphatasia. Am J Med. 1948;22(5):730-46.

5. Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A Molecular-Based Estimation of the Prevalence of Hypophosphatasia in the European Population. Ann Hum Genet. 2011;75(3):439-45. doi: 10.1111/j.14691809.2011.00642.x.

6. Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334-42. doi: 10.1210/jc.2015-3462.

7. Kosnik-Infinger L, Gendron C, Gordon CB, Pan BS, van Aalst JA, Vogel TW. Enzyme replacement therapy for congenital hypophosphatasia allows for surgical treatment of related complex craniosynostosis: a case series. Neurosurg Focus. 2015;38(5):1-6. doi: 10.3171/2015.2.FOCUS14847.

8. Hofmann C, Jakob F, Seefried L, Mentrup B, Graser S, Plotkin H, et al. Recombinant Enzyme Replacement Therapy in Hypophosphatasia. Subcell Biochem. 2015;76:323-41. doi:10.1007/978-94-017-7197-9_15.

9. Taillandier A, Lia-Baldini AS, Mouchard M, Robin B, Muller F,Simon-Bouy B, et al. Twelve novel mutations in the tissuenonspecific alkaline phosphatase gene (ALPL) in patients with various forms of hypophosphatasia. Hum Mutat. 2001;18(1):83-4.

10. Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. . Nat Rev Endocrinol. 2016;12(4):233-46. doi: 10.1038/nrendo.2016.14.

11. The Tissue Nonspecific Alkaline Phosphatase Gene Mutations Database [Sitio virtual]. Yvelines, Francia: University of Versailles-Saint Quentin; 2019 [actualizado 2019 en.]. Disponible en: http://www.sesep.uvsq.fr/database_hypo/Mutation.html

Most read articles by the same author(s)

Similar Articles

<< < 1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.